SEC Form 4 · accession 0001415889-17-001230
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel B Soland
Director
Period of report
Jul 17, 2017
Accepted (ET)
Jul 19, 2017 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $28.85 | Jul 17, 2017 | A | 15,000 | A | — | Jul 16, 2027 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable at the end of each 3-month period following the date of ACADIA's 2017 Annual Meeting of Stockholders, or June 13, 2017.